We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Genentech Defends Herceptin Dosing Patents Before PTAB

Law360, Alexandria, Va. (May 8, 2018, 9:52 PM EDT) -- Genentech Inc. defended two dosage patents for blockbuster breast cancer drug Herceptin against assertions of obviousness by Hospira Inc. by telling a Patent Trial and Appeal Board panel the Pfizer Inc....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.